# Mirion Technologies, Inc.: financial statements, quarterly

MIR · NYSE · CIK 1809987 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mir.md) · [Financials](/companies/mir/financials.md) · [Filings](/companies/mir/filings.md) · [Insiders](/companies/mir/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mir/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [191](/filings/0001628280-24-044338.md) | [230 d](/filings/0001628280-26-009869.md) | [193](/filings/0001628280-25-021106.md) | [207](/filings/0001809987-25-000011.md) | [207](/filings/0001628280-25-047169.md) | [254 d](/filings/0001628280-26-009869.md) | [202](/filings/0001628280-26-028363.md) | [223](/filings/0001628280-26-050604.md) | [223](/filings/0001628280-25-047169.md) | [277 d](/filings/0001628280-26-009869.md) | [258](/filings/0001628280-26-028363.md) | [267](/filings/0001628280-26-050604.md) |
| Cost of revenue | $m | [110](/filings/0001628280-23-036439.md) | [122 d](/filings/0001628280-24-007670.md) | [106](/filings/0001628280-25-021106.md) | [110](/filings/0001809987-25-000011.md) | [114](/filings/0001628280-25-047169.md) | [132 d](/filings/0001628280-26-009869.md) | [106](/filings/0001628280-26-028363.md) | [120](/filings/0001628280-26-050604.md) | [119](/filings/0001628280-25-047169.md) | [142 d](/filings/0001628280-26-009869.md) | [139](/filings/0001628280-26-028363.md) | [134](/filings/0001628280-26-050604.md) |
| Gross profit | $m | [80.8](/filings/0001628280-24-044338.md) | [109 d](/filings/0001628280-26-009869.md) | [87.1](/filings/0001628280-25-021106.md) | [97.4](/filings/0001809987-25-000011.md) | [92.9](/filings/0001628280-25-047169.md) | [122 d](/filings/0001628280-26-009869.md) | [96.1](/filings/0001628280-26-028363.md) | [103](/filings/0001628280-26-050604.md) | [105](/filings/0001628280-25-047169.md) | [136 d](/filings/0001628280-26-009869.md) | [119](/filings/0001628280-26-028363.md) | [133](/filings/0001628280-26-050604.md) |
| Research and development | $m | [7.9](/filings/0001628280-24-044338.md) | [7.8 d](/filings/0001628280-26-009869.md) | [7.9](/filings/0001628280-25-021106.md) | [8.8](/filings/0001809987-25-000011.md) | [10.2](/filings/0001628280-25-047169.md) | [8.1 d](/filings/0001628280-26-009869.md) | [8.7](/filings/0001628280-26-028363.md) | [10.0](/filings/0001628280-26-050604.md) | [10.1](/filings/0001628280-25-047169.md) | [10.1 d](/filings/0001628280-26-009869.md) | [9.6](/filings/0001628280-26-028363.md) | [10.1](/filings/0001628280-26-050604.md) |
| Selling, general and administrative | $m | [83.7](/filings/0001628280-24-044338.md) | [87.3 d](/filings/0001628280-26-009869.md) | [84.1](/filings/0001628280-25-021106.md) | [87.5](/filings/0001809987-25-000011.md) | [84.3](/filings/0001628280-25-047169.md) | [85.2 d](/filings/0001628280-26-009869.md) | [78.7](/filings/0001628280-26-028363.md) | [82.6](/filings/0001628280-26-050604.md) | [87.0](/filings/0001628280-25-047169.md) | [99.9 d](/filings/0001628280-26-009869.md) | [106](/filings/0001628280-26-028363.md) | [105](/filings/0001628280-26-050604.md) |
| Operating income | $m | [(11.1)](/filings/0001628280-24-044338.md) | [13.4 d](/filings/0001628280-26-009869.md) | [(4.9)](/filings/0001628280-25-021106.md) | [2.3](/filings/0001809987-25-000011.md) | [(1.6)](/filings/0001628280-25-047169.md) | [29.0 d](/filings/0001628280-26-009869.md) | [8.7](/filings/0001628280-26-028363.md) | [9.9](/filings/0001628280-26-050604.md) | [7.4](/filings/0001628280-25-047169.md) | [25.5 d](/filings/0001628280-26-009869.md) | [3.7](/filings/0001628280-26-028363.md) | [17.9](/filings/0001628280-26-050604.md) |
| Interest expense | $m | [15.5](/filings/0001628280-24-044338.md) | [15.8 d](/filings/0001628280-26-009869.md) | [15.5](/filings/0001628280-24-019463.md) | [15.1](/filings/0001628280-24-034412.md) | [14.1](/filings/0001628280-24-044338.md) | [13.2 d](/filings/0001628280-26-009869.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.8)](/filings/0001628280-24-044338.md) | [(3.5) d](/filings/0001628280-26-009869.md) | [1.2](/filings/0001628280-25-021106.md) | [0.7](/filings/0001809987-25-000011.md) | [1.0](/filings/0001628280-25-047169.md) | [(0.2) d](/filings/0001628280-26-009869.md) | [0.2](/filings/0001628280-26-028363.md) | [(0.7)](/filings/0001628280-26-050604.md) | [(1.9)](/filings/0001628280-25-047169.md) | [5.3 d](/filings/0001628280-26-009869.md) | [(1.8)](/filings/0001628280-26-028363.md) | [3.2](/filings/0001628280-26-050604.md) |
| Net income | $m | [(12.1)](/filings/0001628280-24-044338.md) | [(15.2) d](/filings/0001628280-26-009869.md) | [(25.8)](/filings/0001628280-25-021106.md) | [(11.7)](/filings/0001809987-25-000011.md) | [(13.6)](/filings/0001628280-25-047169.md) | [15.0 d](/filings/0001628280-26-009869.md) | [0.3](/filings/0001628280-26-028363.md) | [8.3](/filings/0001628280-26-050604.md) | [2.9](/filings/0001628280-25-047169.md) | [17.3 d](/filings/0001628280-26-009869.md) | [(3.4)](/filings/0001628280-26-028363.md) | [7.7](/filings/0001628280-26-050604.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001628280-24-044338.md) | not reported | [(0.13)](/filings/0001628280-25-021106.md) | [(0.06)](/filings/0001809987-25-000011.md) | [(0.07)](/filings/0001628280-25-047169.md) | not reported | [0.00](/filings/0001628280-26-028363.md) | [0.03](/filings/0001628280-26-050604.md) | [0.01](/filings/0001628280-25-047169.md) | not reported | [(0.01)](/filings/0001628280-26-028363.md) | [0.03](/filings/0001628280-26-050604.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0001628280-24-044338.md) | not reported | [(0.13)](/filings/0001628280-25-021106.md) | [(0.06)](/filings/0001809987-25-000011.md) | [(0.07)](/filings/0001628280-25-047169.md) | not reported | [0.00](/filings/0001628280-26-028363.md) | [0.04](/filings/0001628280-26-050604.md) | [0.01](/filings/0001628280-25-047169.md) | not reported | [(0.01)](/filings/0001628280-26-028363.md) | [0.03](/filings/0001628280-26-050604.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [101](/filings/0001628280-23-036439.md) | [129](/filings/0001628280-26-009869.md) | [120](/filings/0001628280-24-019463.md) | [122](/filings/0001628280-24-034412.md) | [133](/filings/0001628280-24-044338.md) | [175](/filings/0001628280-26-009869.md) | [186](/filings/0001628280-25-021106.md) | [263](/filings/0001809987-25-000011.md) | [933](/filings/0001628280-25-047169.md) | [412](/filings/0001628280-26-050604.md) | [398](/filings/0001628280-26-028363.md) | [419](/filings/0001628280-26-050604.md) |
| Current assets | $m | [513](/filings/0001628280-23-036439.md) | [539](/filings/0001628280-25-008233.md) | [515](/filings/0001628280-24-019463.md) | [515](/filings/0001628280-24-034412.md) | [547](/filings/0001628280-24-044338.md) | [595](/filings/0001628280-26-009869.md) | [590](/filings/0001628280-25-021106.md) | [693](/filings/0001809987-25-000011.md) | [1,387](/filings/0001628280-25-047169.md) | [894](/filings/0001628280-26-050604.md) | [891](/filings/0001628280-26-028363.md) | [901](/filings/0001628280-26-050604.md) |
| Total assets | $m | [2,659](/filings/0001628280-23-036439.md) | [2,719](/filings/0001628280-25-008233.md) | [2,649](/filings/0001628280-24-019463.md) | [2,627](/filings/0001628280-24-034412.md) | [2,654](/filings/0001628280-24-044338.md) | [2,636](/filings/0001628280-26-009869.md) | [2,626](/filings/0001628280-25-021106.md) | [2,738](/filings/0001809987-25-000011.md) | [3,496](/filings/0001628280-25-047169.md) | [3,588](/filings/0001628280-26-050604.md) | [3,536](/filings/0001628280-26-028363.md) | [3,521](/filings/0001628280-26-050604.md) |
| Current liabilities | $m | [228](/filings/0001628280-23-036439.md) | [266](/filings/0001628280-25-008233.md) | [235](/filings/0001628280-24-019463.md) | [236](/filings/0001628280-24-034412.md) | [253](/filings/0001628280-24-044338.md) | [263](/filings/0001628280-26-009869.md) | [265](/filings/0001628280-25-021106.md) | [272](/filings/0001809987-25-000011.md) | [287](/filings/0001628280-25-047169.md) | [316](/filings/0001628280-26-050604.md) | [279](/filings/0001628280-26-028363.md) | [282](/filings/0001628280-26-050604.md) |
| Total liabilities | $m | [1,116](/filings/0001628280-23-036439.md) | [1,169](/filings/0001628280-25-008233.md) | [1,131](/filings/0001628280-24-019463.md) | [1,063](/filings/0001628280-24-034412.md) | [1,079](/filings/0001628280-24-044338.md) | [1,077](/filings/0001628280-26-009869.md) | [1,069](/filings/0001628280-25-021106.md) | [1,224](/filings/0001809987-25-000011.md) | [1,604](/filings/0001628280-25-047169.md) | [1,671](/filings/0001628280-26-050604.md) | [1,647](/filings/0001628280-26-028363.md) | [1,646](/filings/0001628280-26-050604.md) |
| Long-term debt | $m | [684](/filings/0001628280-23-036439.md) | [685](/filings/0001628280-25-008233.md) | [685](/filings/0001628280-24-019463.md) | [684](/filings/0001628280-24-034412.md) | [685](/filings/0001628280-24-044338.md) | [685](/filings/0001628280-26-009869.md) | [686](/filings/0001628280-25-021106.md) | [445](/filings/0001809987-25-000011.md) | [443](/filings/0001628280-25-047169.md) | [443](/filings/0001628280-26-050604.md) | [444](/filings/0001628280-26-028363.md) | [444](/filings/0001628280-26-050604.md) |
| Current portion of debt | $m | [0.1](/filings/0001628280-23-036439.md) | [1.2](/filings/0001628280-25-008233.md) | [0.1](/filings/0001628280-24-019463.md) | [0.1](/filings/0001628280-24-034412.md) | [0.6](/filings/0001628280-24-044338.md) | [1.2](/filings/0001628280-26-009869.md) | [0.7](/filings/0001628280-25-021106.md) | [0.4](/filings/0001809987-25-000011.md) | [1.6](/filings/0001628280-25-047169.md) | [1.6](/filings/0001628280-26-050604.md) | [1.6](/filings/0001628280-26-028363.md) | [1.6](/filings/0001628280-26-050604.md) |
| Shareholders' equity | $m | [1,479](/filings/0001628280-23-036439.md) | [1,485](/filings/0001628280-25-008233.md) | [1,457](/filings/0001628280-24-019463.md) | [1,508](/filings/0001628280-24-034412.md) | [1,519](/filings/0001628280-24-044338.md) | [1,506](/filings/0001628280-26-009869.md) | [1,504](/filings/0001628280-25-021106.md) | [1,462](/filings/0001809987-25-000011.md) | [1,841](/filings/0001628280-25-047169.md) | [1,866](/filings/0001628280-26-050604.md) | [1,838](/filings/0001628280-26-028363.md) | [1,826](/filings/0001628280-26-050604.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [23.8 d](/filings/0001628280-24-044338.md) | [67.0 d](/filings/0001628280-26-009869.md) | [6.0](/filings/0001628280-25-021106.md) | [15.2 d](/filings/0001809987-25-000011.md) | [17.1 d](/filings/0001628280-25-047169.md) | [60.8 d](/filings/0001628280-26-009869.md) | [35.6](/filings/0001628280-26-028363.md) | [12.4 d](/filings/0001628280-26-050604.md) | [22.3 d](/filings/0001628280-25-047169.md) | [73.0 d](/filings/0001628280-26-009869.md) | [18.9](/filings/0001628280-26-028363.md) | [58.5 d](/filings/0001628280-26-050604.md) |
| Capital expenditure | $m | [9.4 d](/filings/0001628280-24-044338.md) | [11.9 d](/filings/0001628280-26-009869.md) | [12.8](/filings/0001628280-25-021106.md) | [11.1 d](/filings/0001809987-25-000011.md) | [13.2 d](/filings/0001628280-25-047169.md) | [11.7 d](/filings/0001628280-26-009869.md) | [8.5](/filings/0001628280-26-028363.md) | [8.8 d](/filings/0001628280-26-050604.md) | [9.3 d](/filings/0001628280-25-047169.md) | [9.8 d](/filings/0001628280-26-009869.md) | [9.5](/filings/0001628280-26-028363.md) | [10.4 d](/filings/0001628280-26-050604.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-044338.md) | [(0.4) d](/filings/0001628280-26-009869.md) | [0.0](/filings/0001628280-25-021106.md) | [0.0 d](/filings/0001809987-25-000011.md) | [0.0 d](/filings/0001628280-25-047169.md) | [0.0 d](/filings/0001628280-26-009869.md) | [18.6](/filings/0001628280-26-028363.md) | [31.0 d](/filings/0001628280-26-050604.md) | [0.0 d](/filings/0001628280-25-047169.md) | [0.0 d](/filings/0001628280-26-009869.md) | [16.0](/filings/0001628280-26-028363.md) | [25.0 d](/filings/0001628280-26-050604.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [181](/filings/0001628280-23-036439.md) | [188](/filings/0001628280-24-019463.md) | [199](/filings/0001628280-24-034412.md) | [199](/filings/0001628280-24-044338.md) | [200](/filings/0001628280-25-021106.md) | [202](/filings/0001809987-25-000011.md) | [207](/filings/0001628280-25-047169.md) | [227](/filings/0001628280-26-028363.md) | [243](/filings/0001628280-26-050604.md) | [256](/filings/0001628280-25-047169.md) | [245](/filings/0001628280-26-028363.md) | [275](/filings/0001628280-26-050604.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.